Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children Wit

NCT03088267 is registered in ClinicalTrials.gov with Tris Pharma, Inc. as lead sponsor.

NCT NCT03088267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03088267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children Wit
Lead sponsor
Tris Pharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 11, 2017
Completion date
October 30, 2017
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder